ScreenerHero

CNSPCNS Pharmaceuticals, Inc.

NAS · US · Healthcare · Biotechnology · cnspharma.com
5.830USD0.00%Mkt Cap: 8.52M $P/E: —

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap8.52M $
Enterprise Value-11.22M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-15.85M $
Revenue/Share—
Last Price5.830 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees8
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-15.38
PEG—
EV/EBITDA0.66
EV/Revenue—
P/S—
P/B0.48
EPS (TTM)-15.52
EPS (Forward)-0.39
52W Range
1.90045% of range10.59
52W High10.59 USD
52W Low1.900 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-350.48%
ROA-183.81%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-13.81M $
CapEx (TTM)18.18K $
FCF Margin—
FCF Yield-93.18%
Net Debt-19.98M $
Net Debt/EBITDA1.18
Balance Sheet
Debt/Equity0.07
Current Ratio5.87
Quick Ratio5.35
Book Value/Sh12.45 USD
Cash/Share13.68 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:12
Split DateJul 22, 2025
Analyst Consensus
Rating—
Target (Mean)10.00 USD
Upside (mean)+71.5%
Target Range10.00 USD – 10.00 USD
# Analysts1
Ownership
Shares Out.1.46M
Float1.32M
Insiders0.81%
Institutions21.25%
Short Interest
Short Ratio1.2d
Short % Float0.78%
Short % Out.0.78%
Shares Short11.37K
Short (prev mo.)36.29K
Technical
SMA 505.049 (+15.5%)
SMA 2004.885 (+19.3%)
Beta0.98
S&P 52W Chg18.16%
Avg Vol (30d)7.04K
Avg Vol (10d)8.68K
Technical Indicators
RSI (14)58.5
MACD0.1507
MACD Signal0.1183
MACD Hist.+0.0324
BB Upper5.946 USD
BB Middle5.349 USD
BB Lower4.752 USD
BB Width22.33%
ATR (14)0.4308 USD
Vol Ratio (20d)1.26x